A single-arm, prospective, multicentre, open-label study to evaluate ofatumumab treatment effectiveness and patient reported outcomes in patients with relapsing multiple sclerosis transitioning from dimethyl fumarate or fingolimod therapy

drug protocol number
COMB157G23101
drug sponsor
Novartis
drug study
Ofatumumab
drug trial site
King Faisal Specialist Hospital and Research Center (Jeddah)
drug status
Ongoing
drug phase